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Abstract 
Lecithin cholesterol acyltransferase (LCAT) plays a key role in the reverse cholesterol 
transport (RCT) process by converting cholesterol to cholesteryl ester to form mature 
HDL particles, which in turn deliver cholesterol back to the liver for excretion and catabo-
lism. HDL levels in human plasma are negatively correlated with cardiovascular risk and HDL 
functions are believed to be more important in atheroprotection. This study investigates 
whether and how D-4F, an apolipoprotein A-I (apoA-I) mimetic peptide, influences LCAT 
activity in the completion of the RCT process. We demonstrated that the apparent rate 
constant value of the LCAT enzyme reaction gives a measure of LCAT activity and deter-
mined the effects of free metals and a reducing agent on LCAT activity, showing an inhibition 
hierarchy of Zn
2+>Mg
2+>Ca
2+ and no inhibition with β-mercaptoethanol up to 10 mM. We 
reconstituted nano-disc particles using apoA-I or D-4F with phospholipids. These particles 
elicited good activity in vitro in the stimulation of cholesterol efflux from macrophages 
through the ATP-binding cassette transporter A1 (ABCA1). With these particles we studied 
the LCAT activity and demonstrated that D-4F did not activate LCAT in vitro. Furthermore, 
we have done in vivo experiments with apoE-null mice and demonstrated that D-4F (20 
mg/kg body weight, once daily subcutaneously) increased LCAT activity and HDL level as 
well as apoA-I concentration at 72 hours post initial dosing. Finally, we have established a 
correlation between HDL concentration and LCAT activity in the D-4F treated mice. 
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1. Introduction 
Cardiovascular disease (CVD) remains the 
leading cause of death in developed countries and is 
estimated to be the leading cause of death in devel-
oping countries by 2010 despite advanced medical 
therapies. Atherosclerosis, the process of accumulat-
ing cholesterol in the arteries, leads to clinical events 
such as myocardial infarction and stroke. It is well 
documented that high density lipoprotein (HDL) is 
inversely correlated with coronary heart diseases. 
HDL involves a multi-step physiological process that 
transports excess cholesterol from the peripheral tis-
sues including atherogenic foam cells or macrophages 
in plaques to the liver for catabolism and excretion [1]. 
This process is called reverse cholesterol transport 
(RCT) and has been considered an essential function 
for atheroprotection by HDL. In addition, niacin and 
fibrates that increase HDL level have been used in 
clinics to prevent atherosclerotic progression. How-
ever, Torcetrapib, a cholesterol ester transfer protein 
(CETP) inhibitor that dramatically increases plasma 
HDL levels, recently failed in the Phase III clinical trial 
due to an increased risk of death and cardiac events. Int. J. Biol. Sci. 2009, 5 
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Therefore, the research focus has greatly shifted from 
HDL concentration to HDL functions such as its 
anti-inflammatory [2], anti-oxidant, and 
anti-thrombotic [3] functions; its stimulation of 
ABCG1-dependent cholesterol efflux [4]; its 
SR-BI-dependent delivery of cholesterol to the liver [5, 
6]; and its increase of lecithin cholesterol acyltrans-
ferase (LCAT) activity. Although HDL is still believed 
to play an important role in atheroprotection, the 
lesson learned from the Torcetrapib experience is that 
the detailed understanding of HDL functions, me-
tabolism and its metabolic regulators, as well as their 
relationship with HDL compositions, is critically im-
portant for the development of new therapies. 
ApoA-I, the key protein in HDL, is receiving increas-
ing attention for developing treatments for athero-
sclerosis. Overexpression of apoA-I decreased 
atherosclerosis in animal studies [7, 8]. Infusion of the 
complexes of phospholipids and apoA-I or its genetic 
variant (R173C), apoA-IMilano, showed 
anti-atherosclerotic effects in animals and humans 
[9-13]. The benefit of apoA-I has been demonstrated to 
be directly involved in all steps of RCT process [14]. 
However, due to the high cost of production of apoA-I 
protein, the limitation of structural diversity, and 
limited route of administration, small peptides that 
can mimic apoA-I activities have been explored as 
new therapeutic agents for the treatment of athero-
sclerosis. Numerous mimetic peptides exhibit 
anti-atherosclerotic properties in different animal 
models and a few, such as D-4F and ETC-642 [15] are 
moving into human clinical trials. However, like 
apoA-I itself, the precise mechanism of these peptides 
that is responsible for atheroprotection remains un-
clear [16]. Most of these peptides, if not all, share 
amphipathic properties. Similar to apoA-I, these pep-
tides interact with phospholipids and stimulate cho-
lesterol efflux from microphages and foam cells, 
however, their effects on LCAT activity and other 
activities independent of RCT vary. This study inves-
tigated the biochemical characteristics of the LCAT 
enzyme and determined the effects of D-4F on the 
stimulation of LCAT activity both in vitro and in vivo, 
demonstrating a correlation between HDL level and 
LCAT activity in mice.  
2. Materials and Methods 
2.1. Reagents  
All reagents were obtained from Sigma (St. 
Louis, MO) unless otherwise indicated. Cholesterol 
was from Steraloids Inc. (Cat. C6760; Newport, RI). 
[3H]cholesterol (40 Ci/mmol) was from PerkinElmer 
Life Sciences (Cat. NET139001MC; Waltham, MA). 
The LCAT activity assay kit was from EMD Biosci-
ences (Cat. 428900; San Diego, CA). The Total Cho-
lesterol E and HDL Cholesterol Kits were from Wako 
Chemical USA Inc. (Cat. 439-17501; Richmond, VA). 
The 4-20% Tris-Glycine native gradient gel and run-
ning buffer were from Invitrogen (Calsbad, CA) and 
the high molecular weight marker was from GE 
healthcare (Cat. 17-0445-01; Piscataway, NJ). Purified 
human apoA-I, rabbit anti-mouse apoA-I antibody, 
and purified mouse apoA-I were from Meridian Life 
Science Inc. (Cincinnati, OH). Goat anti-mouse apoA-I 
polyclonal antibody was from Rockland Immuno-
chemicals Inc. (600-101-196; Gilbertsville, PA). 
DELFIA Eu-N1-labeled anti-rabbit antibody and En-
hancement solution were from PerkinElmer Life Sci-
ences (Waltham, MA). The BCA Protein Assay Kit 
was from Pierce Biotechnology (Cat. 23227; Rockford, 
IL). 
2.2. In vivo study  
ApoE-null mice were purchased from Jackson 
Laboratories (Bal Harbor, Maine). All animal experi-
mental procedures followed the NIH guideline and 
were approved by the Merck Research Laboratories 
Instututional Animal Care and Use Committee. Mice 
were enrolled at 24 weeks of age after feeding with a 
high fat Western diet (HF; Harlan Teklad TD#88137) 
for 20 weeks. The D-4F peptide was prepared in PBS 
solution containing 50 mM mannitol and dosed at 20 
mg/kg body weight subcutaneously once daily for 3 
days except where indicated. Samples were collected 
at each designated time point and were added to 
tubes containing EDTA. Plasma was isolated by cen-
trifugation and kept frozen at -80ºC for further analy-
sis.  
2.3. Determination of plasma LCAT activity  
Mouse plasma LCAT activity was determined 
using the LCAT Activity Assay Kit according to the 
manufacturer's instructions with some modifications. 
Briefly, 5 µl aliquots of mouse plasma were incubated 
at 37ºC with the fluorescently labeled cholesterol in 
assay buffer containing 150 mM NaCl, 10 mM 
Tris-HCl, 4 mM β-mercaptoethanol and 1 mM EDTA 
at pH 7.4. The total assay volume was 200 µl. After 0, 
20 and 40 min., 45 µl of the reaction mixture was 
added to 135 µl of the READ reagent (150 mM NaCl, 
10 mM Tris-HCl, and 1 mM EDTA at pH 7.4). The 
conversion of cholesterol (Em. 470 nm) to cholesteryl 
ester (Em. 390 nm) at 340 nm excitation was deter-
mined in a fluorescence microplate reader (SPEC-
TRAmax GEMINI, Molecular Devices Co., Sunnyvale, 
C A ) .  T h e  c h a n g e  o f  r a t i o of the two intensities 
(470/390) was calculated. Int. J. Biol. Sci. 2009, 5 
 
http://www.biolsci.org 
491
2.4. Preparation of HDL associated LCAT en-
zyme  
Fresh human or mouse blood was drawn into 
tubes containing potassium EDTA (Becton Dickinson, 
Franklin lakes, NJ), and plasma was separated imme-
diately by low-speed centrifugation at 2500 rpm 
(1430g ) for 30 min at 4ºC. Size exclusion chromatog-
raphy was performed at ambient temperature using a 
Superose-6 10/300 column on a Bio-Rad FPLC system 
(Hercules, CA). A 200 µl aliquot of plasma was in-
jected per run, and eluted in PBS with 1 mM EDTA at 
a flow rate 0.2 ml/min. A total of 72 fractions with 
0.27 ml per fraction were directly collected into mi-
crotiter plate for further analysis. Total cholesterol in 
each fraction was measured using the Cholesterol E 
Kit, according to the manufacturer's instructions. 
LCAT activity was measured using the LCAT Activity 
Assay Kit as described above (Fig. 1). HDL fractions 
containing LCAT activity were pooled and stored at 
-80ºC. Protein concentration was determined by BCA. 
 
 
Figure 1.  Preparation of HDL associated 
LCAT. Size exclusion chromatography was performed 
at ambient temperature using a Superose-6 10/300 column 
on a Bio-Rad FPLC system (Hercules, CA). A 200 µl ali-
quot of plasma was injected per run, and eluted in PBS 
with 1 mM EDTA at a flow rate of 0.2 ml/min. Total 
cholesterol in each fraction was measured using the 
Cholesterol E Kit. LCAT activity was determined as fol-
lowing: A. 20 µl of each fraction of human plasma were 
incubated at 37ºC for 5 h; B. 2.5 µl of each fraction of WT 
mouse plasma were incubated at 37ºC for 2 h; C. 10 µl of 
each fraction of apoE-null mouse plasma were incubated at 
37ºC for 4 h. 
 
2.5. LCAT substrate preparation  
The substrate particles composed of 
L-α-Phosphatidylcholine derived from egg yolk 
phosphatidylcholine (EPC), cholesterol with 1% of 
[3H]cholesterol, and human apoA-I with a molar 
ratio of 100:10:1 as described [17, 18] with some 
modification. The molar ratio was 100:10:10 if D-4F 
peptide was used. A control EPC-cholesterol vesicle 
was also made at a molar ratio of 100:10. After ly-
ophilizing EPC and cholesterol, apoA-I or D-4F and 
assay buffer (10 mM Tris, 140 mM NaCl, and 1 mM 
EDTA, pH 7.4) were added to the dry powder. The 
particles were created by sonication on ice with a 
microtip at power 23 for 5 min x 5 times with a 2 min 
pause between each cycle followed by centrifugation 
at 1000 rpm (228g) for 5 min at 4ºC. The supernatant 
was kept at 4ºC for further characterization. The 
particles were confirmed by native gradient gel elec-
trophoresis and the size of particles was determined 
against high molecular weight markers (data not 
shown). 
2.6. LCAT activation assay  
In the LCAT activation assay, the synthetic par-
ticles were used as substrates. After a 15 min incuba-
tion of 8 µl of 10-fold diluted substrates with 0.6% 
bovine serum albumin (fatty acid free) in assay buffer 
mentioned above, β-mercaptoethanol was added to a 
final concentration of 2 mM. The LCAT reaction was 
initiated by addition of 2 µl HDL associated-human 
LCAT and total volume was brought to 40 µl. After 5 
hours at 37 ºC the reaction was quenched by freezing 
the samples in a -80ºC freezer. After the samples were 
thawed, 20 µl aliquots were spotted on silica TLC 
plates. The cholesterol and cholesteryl esters were 
then separated by thin-layer chromatography in pe-
troleum ether/diethyl ether/acetic acid (80:30:1, 
v/v/v) mixture. The cholesterol and cholesteryl ester Int. J. Biol. Sci. 2009, 5 
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bands were scraped and counted in scintillation 
cocktail. The percentage conversion of cholesterol to 
cholesteryl ester was quantified by their respective 
associated radioactivity.  
2.7. Cholesterol efflux assay  
Mouse macrophage cells (RAW 264.7, ATCC) 
were cultured in Dulbecco's Modified Eagle Medium 
(Invitrogen 12491) with 10% FCS and 1% Pen Strep 
Glutamine (GIBCO 10378) in T225 flasks to a conflu-
ency of ~80%. The cells were then seeded into 48 well 
plates at a concentration of 1 x 105 cells/0.2 ml /well 
in the same medium now supplemented with 3[H] 
cholesterol (Perkin-Elmer) to a final 5 µCi/ml. After 
24 hours, the cells were washed once and starved 
overnight with serum-free medium supplemented 
with 0.1% lipid-free BSA. Finally, apoA1 and D-4F 
with or without cAMP in serum-free medium were 
added and incubated for another 24 hours. Subse-
quently, medium and cell lysate (0.5% Triton X-100 in 
1 mM HEPES, pH 7.5) were collected and aliquots 
were mixed separately with scintillation cocktail and 
counted. Cholesterol efflux was calculated as the 
percentage of radioactivity associated with medium 
over the sum of radioactivity of both medium and 
lysate. The cAMP-dependent cholesterol efflux was 
determined by the difference between cholesterol 
measured in the presence and the absence of cAMP. 
2.8. Other assays  
Plasma total cholesterol and HDL were quanti-
fied by Wako cholesterol kits. Apolipoprotein A-I was 
determined by ELISA and Western blot using rabbit 
anti-mouse apoA-I and quantified against purified 
mouse apoA-I. In the ELISA assay, the plates were 
coated with goat anti-mouse apoA-I polyclonal anti-
body at a concentration of 0.5 µg/ml overnight at 4°C. 
After blocking, the purified mouse apoA-I standard 
was diluted to 50 ng/ml, and then 2 fold serial dilu-
tion, and mouse plasma samples were diluted 50,000 
times in assay buffer, 100 µl diluted samples were 
added to the wells and incubated at 37°C for 2 hours. 
Subsequently, rabbit anti-mouse apoA-I antibody was 
added and incubated at 37°C for 1 hour. Finally, 
DELFIA Eu-N1-labeled anti-rabbit antibody was 
added and incubated at room temperature for 30 
minutes. The signal was detected by adding the en-
hancement solution and measured in an EnVision 
multilabel plate reader.  
3. Results 
3.1. Determination of enzyme kinetics  
In addition of apoA-I, apoE is an important pro-
tein in the lipoprotein transport system. The athero-
protective properties of apoE has been demonstrated 
in numerous models. ApoE-null mice on a high 
fat/high cholesterol diet has also been well docu-
mented as an animal model for atherosclerosis [19]. 
Wild type (WT) and apoE-null mice have different 
lipoprotein profiles, in that WT mice have high HDL 
and very low LDL and VLDL while apoE-null mice 
have high VLDL and very low HDL, with total cho-
lesterol levels approximately 6 times higher than that 
of WT mice. In order to determine the role of LCAT in 
atherogenesis, we purified HDL-associated LCAT 
enzymes and measured their activities in a time 
course study at 37ºC. We used fluorescence-labeled 
cholesterol as substrate and found that cholesteryl 
ester is formed in a dose- and time-dependent manner 
in the presence of LCAT (Fig. 2A). Addition of the 
HDL-associated LCAT increased the rate of choles-
teryl ester formation dramatically. Further, we ana-
lyzed the enzyme kinetics. LCAT reaction is a 
first-order reaction, and rate constants increased line-
arly with increasing amounts of LCAT enzyme (Fig. 
2B), therefore the increase in the rate constant is a 
measure of LCAT activity. We define a unit of LCAT 
activity as an increment in the rate constant kapp of 1.0 
min-1. Here, we observed that the specific LCAT ac-
tivities of WT and apoE-null mice are 0.00199 + 
0.0001058 and 0.001322 + 0.000124 min-1μg-1, respec-
tively, indicating that the specific LCAT activity of 
HDL-associated LCAT enzyme from apoE-null mice 
is 1.5-fold lower than that from WT mice.  
 
Figure 2. Determination of LCAT kinetics. A. 
The assay was performed at 37ºC as described in Int. J. Biol. Sci. 2009, 5 
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Materials and Methods with increasing amounts of 
HDL-associated LCAT purified from wild type (WT) 
mice (∆1.25; ○2.5; ▲5; ●10 μg). The cholesterol was 
converted to cholesteryl ester by LCAT and the re-
action was determined by measuring the change of 
fluorescence intensity ratios (470 nm/390 nm) at dif-
ferent times shown on the abscissa. Similar experi-
ments were performed using HDL-associated LCAT 
purified from apoE-null mice (data not shown). B. 
LCAT activity, presented as the apparent rate con-
stant, kapp, that was obtained from each data set of A, 
plotted against the amount of LCAT added. The 
goodness-of-fit of linear regression (r2) is 0.98 for both 
WT (■) and apoE-null (□) mouse HDL-associated 
LCAT enzymes. Their specific LCAT activities are 
0.00199 + 0.0001058 and 0.001322 + 0.000124 
min-1μg-1 for WT and apoE-null mice, respectively. 
Similar results were obtained in two other experi-
ments. 
 
3.2. Effects of metals and reducing agent on 
LCAT activity  
To optimize the assay condition and understand 
physiological regulation by metals, the effects of di-
valent cations and reducing agent β-mecaptoethanol 
on LCAT activity were examined. We used 
EPC-cholesterol vesicles as substrate and added hu-
man apoA-I at a final concentration of 0.5 µM which 
mimics the condition of the pre-formed particles of 
EPC/Ch/apoA-I (100:10:1, mol/mol/mol). The reac-
tion was initiated by adding HDL-associated human 
LCAT enzyme as described in Materials and Meth-
ods. With the addition of 1 mM EDTA, an inhibition 
hierarchy of Zn2+>Mg2+>Ca2+ was observed, provid-
ing IC50 values of 1.1, 7.3, and 21.7 mM for Zn2+, Mg2+ 
and Ca2+, respectively (Fig. 3A, 3B, 3C). The IC50 ob-
served for Zn2+ is close to the EDTA concentration 
added, therefore the IC50 for free (unchelated) Zn2+ 
m igh t  b e v er y lo w  an d w o uld  n eed  t o  b e c aref ul ly  
determined as described for greater accuracy [20]. No 
inhibition was observed with β-mercaptoethanol at 
concentrations up to 10 mM (Fig. 3D).  
 
 
Figure 3. The effects of divalent cations and β-mecaptoethanol on LCAT activity. The assay was 
performed as described in Materials and Methods with a serial dilution of metals and β-mecaptoethanol. With 
EPC-cholesterol as substrate, 0.5 µM of apoA-1 and 2 μg of HDL-associated human LCAT were added. Fig. A, B, 
and C show an inhibition hierarchy of Zn2+>Mg2+>Ca2+, giving the IC50 values of 1.1 mM , 7.3 mM, and 21.7 mM 
for Zn2+, Mg2+ and Ca2+, respectively. Fig. D shows no inhibition with β-mercaptoethanol up to 10 mM. Error bars 
represent standard deviations of duplication in two independent experiments.  
 Int. J. Biol. Sci. 2009, 5 
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3.3. In vitro LCAT activation properties of apoA-I 
and D-4F  
To investigate the ability of human apoA-I and 
the mimetic peptide D-4F to activate LCAT, apoA-I 
and D-4F particles were synthesized with EPC and 
cholesterol as described in Materials and Methods. 
The particle sizes showed diameters of 8.6-12.2 nm on 
a native gel separated by electrophoresis (data not 
shown). The bands on the native gel were broader 
than particles made with Dipalmitoylphosphatidyl-
choline (DPPC) which had both size and discoidal 
shape confirmed by electron microscope (EM) (Fig. 
4F).  
ABCA1-dependent cholesterol efflux from pe-
ripheral tissues is the first step in the RCT process. In 
the mouse macrophage cell line, RAW 264.7, the basal 
expression level of ABCA1 is very low, but can be 
significantly increased by adding cAMP (Fig. 4A). 
This characteristic is useful for determining the 
ABCA1-dependent cholesterol efflux in vitro. ApoA-I 
added to RAW cells without cAMP produced almost 
no efflux activity, but in the presence of cAMP efflux 
levels increased dramatically (Fig. 4B). The activities 
of free apoA-I, apoA-I particles, free D-4F and D-4F 
particles in the stimulation of ABCA1-dependent 
cholesterol efflux from macrophages were assayed, 
resulting in EC50 values of 101 nM, 103 nM, 2.2 μM 
and 2.8 μM, respectively (Fig. 4C, 4D). ApoA-I or D-4F 
particles or EPC-cholesterol vesicles were used as 
substrates in the LCAT activation assay. As shown in 
Fig. 5A and 5B, human HDL-associated LCAT had a 
basal LCAT activity converting 4.6% to cholesteryl 
ester; proteoliposome containing ApoA-I increased 
LCAT activity by 5.9 fold while peptidosome con-
taining D-4F showed no LCAT activation in the assay. 
 
 
 
 
 
Figure 4. ABCA1 dependent cholesterol efflux assay. The assay details are described in Materials and 
Methods. A, ABCA1 expression levels in RAW cells were determined by western blot with anti-mouse ABCA1 
antibody. Very low basal expression levels of ABCA1 are dramatically increased by the addition of cAMP. B, 
apoA-I-stimulated cholesterol efflux from macrophage is ABCA1 level dependent. C, apoA-I and its formulated 
particles show activity in stimulating cholesterol efflux through the ABCA1 transporter, providing EC50 values of 
101 nM and 103 nM, respectively. D, D-4F and its formulated particles show activity in stimulating cholesterol 
efflux through the ABCA1 transporter, providing EC50 values of 2.2 μM and 2.8 μM, respectively. F, both size and 
discoidal shape of D-4F particles made with Dipalmitoylphosphatidylcholine (DPPC) (D4F:DPPC = 1:10) were confirmed by 
electron microscope (Magnification 45000, disk size; 6 x 12 nm). 
 Int. J. Biol. Sci. 2009, 5 
 
 
http://www.biolsci.org 
495
The ability of apoA-I and D-4F to activate LCAT 
activity was also determined using the method that 
Datta et al. used to demonstrate LCAT activation by 
the 5F and 6F, analogs of D-4F [21]. Following that 
method, our EPC-cholesterol vesicles were used as 
substrates and apoA-I and D-4F were titrated (Fig. 
5C). Again, apoA-I showed a dose-dependent activa-
tion of LCAT with an EC50 of 72.8 nM, while D-4F was 
unable to activate LCAT up to 28 µg/ml (12.1 μM).  
 
 
Figure 5. LCAT activation with apoA-1 and 
D4F peptide. A, phosphorimaging results of LCAT 
assay. The assay was performed as described in Ma-
terials and Methods. Pre-formed 
apoA1/EPC/cholesterol (a), D-4F/EPC/cholesterol (b) 
and EPC-cholesterol particles (c) as substrates, incu-
bated with 2 μg of HDL- associated human LCAT (left 
panel) or assay buffer (right panel) at 37ºC. After 5 
hours the reaction was stopped by freezing the sam-
ples. The cholesteryl ester formed was separated from 
free cholesterol by TLC and visualized by phosphoi-
maging. B, production of cholesteryl ester from the 
same assay. The cholesterol and cholesteryl ester 
bands on TLC plate were also visualized by exposing 
the plate to iodide vapour and the visible bands were 
scraped from the plate and counted for [3H] signal in 
scintillation fluid. The conversion of cholesterol to 
cholesteryl ester was calculated based on their asso-
ciated radioactivity. Experiments were done at least 
three times in duplicates. C, EPC/cholesterol vesicle as 
substrate. Increasing amounts of apoA-1 (●) and D-4F 
(▲) were incubated with 2 μg partially purified HDL- 
associated human LCAT. Error bars represent two 
independent experiments with duplication.  
3.4. Dosing D-4F in mice  
In light of the effect of D-4F on LCAT activity in 
vitro, we performed additional experiments to meas-
ure plasma LCAT activity after treatment with D-4F in 
vivo. 20 mg/kg of D-4F peptide or 50 mM mannitol 
were injected into apoE-null mice as a single dose or 
once daily for 3 days. Twenty-four hours after a single 
dose (24 h) or after last injection of three doses (72 h), 
mice were sacrificed and plasma samples were ana-
lyzed for different parameters. A significant increase 
of LCAT activity was observed in the 72 h D-4F 
treated group but not in the 24 h group (Fig. 6A). The 
plasma samples were analyzed by FPLC and each 
fraction was assayed for total cholesterol levels. Total 
cholesterol levels increased slightly in the 24 h group 
(1,512 ± 54 mg/dl) and slightly decreased in 72 h 
group (1,218 ± 79 mg/dl) compared to the control 
group (1,301 ± 124 mg/dl), but none reached statisti-
cal significance. Surprisingly, HDL levels did not 
change 24 h after first dose but increased significantly 
24 h after the third dose (from 14.3 ± 3.8 to 28.1 ± 3.5 
mg/dl). When HDL cholesterol concentration was 
plotted against LCAT activity, the treated group (72h) 
had a parallel increase in both LCAT activity and 
HDL level, which demonstrated that LCAT activity is 
positively correlated with plasma HDL cholesterol 
concentration (Fig. 6B). Plasma taken 1 h and 4 h after 
the first dosing of D-4F showed no differences from 
the vehicle controls in LCAT activity or HDL levels, 
even though D-4F reached its highest concentration in 
plasma at 4 h. (data not shown). To understand 
whether the HDL increase is accompanied by an in-
crease in apoA-I, apoA-I ELISAs with rabbit 
anti-mouse apoA-I antibody were done and con-
firmed by western blots. The apoA-I protein in the 72 
h D-4F group significantly increased 1.27-fold com-
pared to the vehicle group (Fig. 6C).  Int. J. Biol. Sci. 2009, 5 
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Figure 6. D-4F increases plasma LCAT activity, HDL, and apoA-I in vivo. ApoE-null mice were injected 
subcutaneously with D-4F peptide at 20 mg/kg once daily for 3 days, and plasma samples were collected at 
different time points. LCAT activity and HDL concentrations were measured as described in Materials and 
Methods. A, plasma LCAT activity of apoE-null mouse after D-4F treatment (□ Vehicle, ■ D-4F treated). The 
plasma samples were collected 24 hours after first (24 h) and third (72 h) dosing. No change of LCAT activity was 
seen at 24 hours after single dosing while a significant increase of LCAT activity was seen 24 hours after the third 
dosing (p = 2x10-6). Results were from two independent experiments. B, correlation between LCAT activity and 
HDL concentration. LCAT activities of control plasma (●) and 24 hr after third dose with D-4F (▼) were plotted 
against their HDL concentrations. The goodness-of-fit of linear regression (r2) is 0.64. C, apoA-I ELISA of 
apoE-null mouse plasma collected from control group (open bar) and 24 hours after third dose with D-4F (closed 
bar). Error bars represented the standard division (*: P<0.05, ***: P<0.001). 
 
4. Discussion 
Lecithin cholesterol acyltransferase (LCAT) is an 
enzyme responsible for free cholesterol (FC) esterifi-
cation, which is critical for HDL maturation and the 
completion of the RCT process. It circulates in plasma, 
primarily associates with HDL, and is activated by 
apoA-I [22, 23]. Genetic mutations in human LCAT 
genes cause familial LCAT deficiency [24] and fish eye 
disease [25], which result in a decrease of plasma HDL 
and accumulation of cholesterol in organs. LCAT ac-
tivity was found significantly decreased in athero-
sclerotic patients [26] and this decrease was accom-
panied by lower HDL cholesterol levels as well as 
lower apoA-I mass due to its rapid catabolism [27, 28]. 
A number of animal models have also been generated 
to investigate the role of LCAT activity in atheroscle-
rosis [29-32]. However, reports showing the effects of 
LCAT on atherosclerosis are controversial. ApoA-I 
mimetic peptides with 18-22 amino acids are designed 
to mimic apoA-I's ability to form class A amphipathic 
helices without sharing the sequence similarity of 
apoA-I protein. Their sequence diversity offers them 
opportunity to surpass apoA-I's atheroprotection. 
However, mimicking all of the atheroprotective 
properties of apoA-I protein (243 amino acids) that 
contains 10 different amphipathic helices with one 
helix could be very challenging. Both mutagenesis 
studies and human genetic data suggest that different 
helices of apoA-I are important for different functions. Int. J. Biol. Sci. 2009, 5 
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For example, the mutations at the N-terminal (helices 
2-7) are associated with familial amyloidosis while the 
mutations at the C-terminal (helices 4-10) are associ-
ated with LCAT activation, despite the fact that these 
mutations are associated with low HDL levels in 
plasma [33]. RCT is a process that requires all proteins 
in the pathway to work in concert. Then, how can a 
mimetic peptide enhance the RCT process if it only 
increases cholesterol efflux from peripheral cells 
without increasing other enzyme and receptor activi-
ties such as LCAT and SR-BI? To answer this question 
we purified HDL-associated LCAT from wild type 
and apoE-null mice and studied LCAT activity and its 
kinetics (Fig. 2). Despite the fact that plasma HDL 
cholesterol concentration is 6-fold lower, apoA-I con-
centration is 1.5-fold lower in apoE-null mice than in 
wild type mice (Fig. 1, 6B, and 6C, data not shown). 
Correspondingly, the specific activity of purified 
HDL-associated LCAT from apoE-null mice is 1.5-fold 
lower than that from wild type mice (Fig. 2), sug-
gesting that 1) the HDL composition alters LCAT ac-
tivity, and 2) poor LCAT activity might play a role in 
apoE-null mice for atherogenesis. In addition, in 
a t h e r o g e n e s i s ,  p o o r  L C A T  a c t i v i t y  m a y  r e s u l t  a s  a  
consequence of enhanced haptoglobin level on apoA-I 
function [16, 34-36]. Since a single amino acid muta-
tion at any place in helices 4-10 of the apoA-I protein 
is associated with LCAT activation, a subtle change in 
a mimetic peptide might alter its capability to activate 
LCAT [21]. To determine the LCAT activation by 
D-4F, we performed two types of assays. One was 
using reconstituted pre-beta nano-particles (peptide/ 
or apoA-I/EPC/cholesterol) as substrates, and initi-
ating the LCAT reaction by the addition of LCAT en-
zyme (Fig. 5A, 5B); another was using EPC-cholesterol 
vesicles as substrate with addition of a serial diluted 
peptide or apoA-I followed by adding LCAT enzyme 
(Fig. 5C). ApoA-I showed good LCAT activation but 
D-4F did not exhibit any activation in either assay. 
This conclusive finding raised interesting questions 
on how D-4F can complete the RCT process and in-
crease cholesterol excretion in vivo [37]. Also, does 
D-4F, as a dominant negative inhibitor, block en-
dogenous apoA-I-induced LCAT activity, which in 
turn increases pre-β HDL and decreases mature HDL 
whose function is considered more important for 
atheroprotection? To address these issues we per-
formed in vivo studies with apoE-null mice. Our study 
with multiple dosing of D-4F in apoE-null mice 
showed that total cholesterol but not HDL cholesterol 
increased at 24 hours after the first subcutaneous in-
jection. However, HDL cholesterol level and apoA-I 
concentration increased 24 hours after the third injec-
tion. Notably, it has been reported in literature that 
D-4F had no effect on total cholesterol or 
HDL-cholesterol concentrations [38]. This discrepancy 
might be due to different animal models, dosing 
regimens, routes of administration, and the time that 
samples were collected. Our study showed that D-4F 
increases LCAT activity in vivo through an increase of 
apoA-I as well as HDL concentration. The correlation 
demonstrated between LCAT and HDL concentra-
tions indicates that the D-4F-induced HDL DOES 
have a good function in stimulating LCAT activity. 
Recently Song et al. (manuscript in preparation) have 
demonstrated that D-4F is capable of forming 
HDL-like particles and delivering cholesterol to the 
liver cells selectively through SR-BI and enhances the 
cholesterol delivery by native HDL. Our results along 
with other in vivo studies [37, 39] suggest that the RCT 
pathway is an important therapeutic target for new 
drug discovery and development for the treatment of 
atherosclerosis.  
Notably, the concentration of total apoA-I pro-
tein in human plasma is in the range of 35-55 μM 
(1-1.5 mg/ml), however the EC50 of LCAT activation 
by free apo A-I is only 72.8 nM (2 μg/ml) (Fig. 5C) 
which is similar to the EC50 values of free or discoidal 
apoA-I in stimulating ABCA1-dependent cholesterol 
efflux (101 or 103 nM, Fig. 4C). These similarities 
suggest that free and discoidal apoA-I are the most 
active forms in reverse cholesterol transport and that 
slight changes of their concentrations in circulation 
might alter RCT process dramatically. These also 
suggest that apoA-I infusion at a very low dose (such 
as 1 mg/kg body weight), reaching a plasma concen-
tration above 100 nM (>EC50) might be sufficient for 
the treatment of atherosclerosis.  
There are many challenges in drug discovery 
[40] and development by targeting HDL. The mecha-
nism of HDL functions and the effects of the complex 
remodeling of the particles' composition are poorly 
understood. There is no ideal mouse model with 
lipoprotein profiles and atherosclerotic lesion biology 
similar to that of humans, partly due to the mouse's 
inherent lack of CETP. In addition, large population 
outcome trials (cost and time consuming) are required 
because high HDL levels alone do not always trans-
late to a clinical benefit. No endpoint surrogates other 
than medical events and death have been validated 
although magnetic resonance imaging (MRI) and in-
travascular ultrasound (IVUS) have shown a great 
potential for application [13]. Therefore, the detailed 
understanding of each agent that targets HDL func-
tions, modulations and its regulations may lead to the 
discovery of good biomarkers and provide valuable 
guidance for clinical trials and applications. Int. J. Biol. Sci. 2009, 5 
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